Transforming growth factor-β and the progression of renal disease

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Loeffler, Ivonne ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

diabetic nephropathy; EMT; fibroblasts; progression of renal diseases; renal fibrosis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULOSCLEROSIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; MESANGIUM CELL; MOLECULAR PATHOLOGY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; RENAL PROTECTION;

DIABETIC NEPHROPATHY; EMT; FIBROBLASTS; PROGRESSION OF RENAL DISEASES; RENAL FIBROSIS;

ANIMALS; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84888643463     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft267     Document Type: Review

References (56)

1. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transduction. J Leukoc Biol 2002; 71: 731-740
2. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700
3. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791
4. Kingsley DM. The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-146
5. Wrana JL, Attisano L, Wieser R et al. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-347
6. Pohlers D, Brenmoehl J, Löffler I et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009; 1792: 746-756
7. Hill CS. The Smads. Int J Biochem Cell Biol 1999; 31: 1249-1254
8. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584
9. Kitamura M, Sütö TS. TGF-beta and glomerulonephritis: Anti-inflammatory versus prosclerotic actions. Nephrol Dial Transplant 1997; 12: 669-679
10. Yamamoto T, Noble NA, Cohen AH et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469
11. Yamamoto T, Watanabe T, Ikegaya N et al. Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. J Am Soc Nephrol 1998; 9: 2253-2261
12. Minto AW, Wilson HM, Rees AJ et al. Selective expression of TGF-beta2 and TGF-beta3 isoforms in early mesangioproliferative glomerulonephritis. Nephron Exp Nephrol 2004; 96: E111-e118
13. Murakami K, Takemura T, Hino S et al. Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr Nephrol 1997; 11: 334-336
14. Goumenos DS, Tsakas S, El Nahas AM et al. Transforming growth factorbeta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 2002; 17: 2145-2152
15. Lee HS. Mechanisms and consequences of TGF-β overexpression by podocytes in progressive podocyte disease. Cell Tissue Res 2012; 347: 129-140
16. Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: Role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115-123
17. Wolf G, Mueller E, Stahl RA et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372
18. Wolf G, Ziyadeh FN, Stahl R. Angiotensin II stimulates expression of transforming growth factor b receptor type II in cultured mouse proximal tubular cells. J Mol Med 1999; 77: 556-564
19. Gewin L, Vadivelu S, Neelisetty S et al. Deleting the TGF-β receptor attenuates acute proximal tubule injury. J Am Soc Nephrol 2012; 23: 2001-2011
20. Docherty NG, Pérez-Barriocanal F, Balboa NE et al. Transforming growth factor-beta1 (TGF-beta1): A potential recovery signal in the post-ischemic kidney. Ren Fail 2002; 24: 391-406
21. Wen X, Murugan R, Peng Z et al. Pathophysiology of acute kidney injury: A new perspective. Contrib Nephrol 2010; 165: 39-45
22. L?pez-Hern?ndez FJ, L?pez-Novoa JM. Role of TGF-β in chronic kidney disease: An integration of tubular, glomerular and vascular effects. Cell Tissue Res 2012; 347: 141-154
23. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 2005; 1: 27-40
24. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405
25. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45
26. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: A metabolic and endocrine disorder. Am J Kidney Dis 2011; 58: 637-646
27. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: P26-p31
28. Böttinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-2610
29. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
30. Schiffer M, Bitzer M, Roberts IS et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816
31. Li Y, Kang YS, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172: 299-308
32. Strutz F, Okada H, Lo CW et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405
33. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350
34. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: Fact or fantasy? J Clin Invest 2011; 121: 468-474
35. Zeisberg M, Duffield JS. Resolved. EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21: 1247-1253
36. Yamaguchi Y, Iwano M, Suzuki D et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54: 653-664
37. Zeisberg EM, Potenta SE, Sugimoto H et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287
38. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin- induced diabetic mice. Am J Pathol 2009; 175: 1380-1388
39. Phillips AO, Steadman R. Diabetic nephropathy: The central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol 2002; 17: 247-252
40. Hills CE, Squires PE. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 2011; 22: 131-139
41. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834
42. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301
43. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-182
44. Meran S, Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 2011; 92: 158-167
45. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475
46. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12
47. Rastaldi MP, Ferrario F, Giardino L et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-146
48. Loeffler I, Liebisch M, Wolf G. Collagen VIII influences epithelial phenotypic changes in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 303: F733-F745
49. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 2009; 175: 1371-1373
50. Kasuga H, Ito Y, Sakamoto S et al. Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis. Kidney Int 2001; 60: 1745-1755
51. Fukasawa H, Yamamoto T, Suzuki H et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/ TGF-beta signaling. Kidney Int 2004; 65: 63-74
52. Petersen M, Thorikay M, Deckers M et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008; 73: 705-715
53. Wang B, Koh P, Winbanks C et al. miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 2011; 60: 280-287
54. Noh H, Kim HJ, Yu MR et al. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor. Lab Invest 2012; 92: 1583-1596
55. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968
56. Trachtman H, Fervenza FC, Gipson DS et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011; 79: 1236-1243